Orthokeratology (Ortho-K) and Advanced Myopia Control in Chennai
Myopia is not just a glasses prescription - it is a progressive disease of the eye. Ortho-K, low-dose atropine, and axial length monitoring give your child a clinically proven way to slow it down before high myopia causes permanent structural damage.
50%
global population myopic by 2050
43-56%
axial growth reduction with Ortho-K
5x
higher retinal detachment risk at high myopia
0.01%
atropine concentration studied in ATOM2 trial
Myopia Is a Disease, Not Just a Prescription
Most parents understand myopia as "needing glasses." What is less well understood is that myopia is driven by the physical elongation of the eyeball. Every year that myopia progresses, the eye grows longer. The longer the eye, the thinner the retina, the choroid, and the sclera become. This stretching is not reversible - and it creates permanent structural changes that raise the lifetime risk of retinal detachment, macular degeneration, glaucoma, and cataract regardless of how well corrected the child's vision is.
In India, myopia prevalence among school-going children in urban areas has risen dramatically over the past two decades. Children are spending more time indoors, more time on near digital tasks, and significantly less time in natural daylight. The result is earlier onset and faster progression.
The goal of myopia control is not to reduce the prescription that a child already has. It is to slow the rate at which the eye continues to grow - reducing the final level of myopia the child reaches by the time their eyes stabilise in their early twenties. Keeping a child at -3.00D instead of -7.00D is not a small difference. It is a potentially life-changing difference in terms of future eye health risk.
Orthokeratology (Ortho-K) - Glasses-Free Days, Slower Myopia Progression
Orthokeratology uses custom-designed rigid gas-permeable contact lenses that the child wears only while sleeping. The lenses gently reshape the corneal surface overnight. When the child wakes and removes the lenses, the cornea temporarily holds its new shape, providing clear vision through the day without any glasses or contact lenses.
Beyond the convenience benefit, Ortho-K is one of the most effective myopia control treatments available. Multiple large-scale studies including the LORIC, ROMIO, and MiSight trials consistently show that Ortho-K reduces the rate of axial elongation by 43 to 56 percent compared to children wearing conventional single-vision glasses. This is a substantial protective effect achieved without surgery or medication.
Ortho-K is most effective when started early - ideally when the prescription is between -1.00D and -5.00D and the child is still in the active growth phase. We assess corneal topography, refractive error, and axial length before prescribing to confirm suitability.
Who Is Ortho-K Suitable For?
Children aged 7 and above with progressing myopia
Prescriptions between -0.75D and -5.00D (with or without mild astigmatism)
Active children and teenagers who dislike wearing glasses during sports
Children progressing by more than -0.50D per year
Not suitable for prescriptions above -5.00D or significant corneal irregularity
Lens care: Ortho-K lenses require daily cleaning and enzyme protein removal. Children need to be motivated to follow the hygiene protocol. We assess readiness during the initial consultation.
How the Ortho-K Process Works
From initial assessment to glasses-free mornings - what to expect at each stage.
Corneal Topography Mapping
We map the exact shape of your child's cornea using computerised topography. This determines the lens design and confirms that Ortho-K is suitable.
Custom Lens Design and Order
Each Ortho-K lens is custom manufactured to your child's corneal data and prescription. The reverse geometry design applies controlled pressure to the central cornea during sleep.
Lens Fitting and Training
Your child inserts the lenses before sleep. We train both parent and child in insertion, removal, and lens care. A follow-up the next morning checks the topographic effect.
First Clear Morning
Most children notice significantly clearer vision from the first morning. Full correction is typically achieved within 1 to 2 weeks of consistent overnight wear.
6-Monthly Axial Length Review
We measure axial length every 6 months to track whether myopia progression has slowed. If progression continues despite Ortho-K, we adjust the treatment plan.
Annual Lens Replacement
Ortho-K lenses are replaced annually or when the prescription changes significantly. The reversibility of the treatment means the effect can be discontinued at any time without permanent corneal change.
Low-Dose Atropine Eye Drops for Myopia Control
Low-dose atropine is a pharmaceutical approach to myopia control. Atropine is a muscarinic receptor antagonist that has been used in ophthalmology for decades at high concentrations to dilate the pupil. Researchers discovered that at very low concentrations - 0.01% to 0.05% - atropine slows myopia progression without the significant side effects of higher doses.
The ATOM2 trial (Atropine for the Treatment of Myopia 2) demonstrated that 0.01% atropine reduced myopia progression by approximately 60% over 2 years, with a rebound effect that was lower than higher concentrations. The more recent LAMP study (Low-Concentration Atropine for Myopia Progression) found that 0.05% atropine provided even greater efficacy with acceptable tolerability, and is now considered the preferred concentration in most clinical protocols.
The mechanism is not fully understood. Unlike the cycloplegia produced by high-dose atropine, low-dose atropine does not work primarily by relaxing the focusing mechanism. Current evidence suggests it acts on scleral and retinal receptors to regulate axial elongation directly. One nightly drop in each eye is the standard protocol.
0.05%
LAMP study preferred concentration - highest efficacy with low side effects
60%
Average reduction in myopia progression over 2 years in clinical trials
1 drop
Per eye nightly at bedtime. Children still wear their regular glasses during the day.
Note: Low-dose atropine is not the same as the cycloplegic atropine drops used to dilate the pupil for examination. The concentrations used for myopia control are 20 to 100 times lower. Side effects at 0.01% to 0.05% are minimal in most children - minor pupil dilation and occasional light sensitivity. Glasses continue to be worn during the day.
Axial Length Monitoring - Why the Prescription Alone Is Not Enough
The standard way to track myopia is to measure how the spectacle prescription changes over time. This is useful but incomplete. Prescription can appear to stabilise while axial elongation continues. Conversely, a small prescription increase may reflect normal variation rather than true progression.
Axial length measurement - the distance from the front of the cornea to the retina in millimetres - is a far more direct and sensitive measure of myopia progression. An increase of just 0.1mm per 6 months is considered clinically significant. Research has shown that axial length is more closely correlated with retinal pathology risk than the spectacle prescription, because retinal stretch depends on physical eye size, not on refraction.
What Axial Length Tells Us That Prescription Does Not
Whether the eye is still elongating even when the prescription looks stable
Whether the myopia control treatment is actually working
The long-term structural risk profile of the eye
When a treatment change or combination therapy may be needed
At Caring Vision Therapy we measure axial length at every myopia control review appointment using non-contact optical biometry. We track each child's axial length over time against age-normal growth curves to give a clear, objective picture of whether their myopia is under control. This data shapes every treatment decision.
Comparing Myopia Control Options
| Factor | Regular Glasses Only | Ortho-K Lenses | Low-Dose Atropine | Ortho-K + Atropine |
|---|---|---|---|---|
| Axial growth reduction | None | 43-56% | ~60% | Up to 80%+ |
| Daytime glasses needed | Yes | No | Yes | No |
| Minimum starting age | Any age | ~7 years | ~4-5 years | ~7 years |
| Reversible | Yes | Yes | Yes | Yes |
| Evidence level | No myopia control benefit | Level I (multiple RCTs) | Level I (ATOM2, LAMP) | Emerging evidence |
| Best suited for | Stable low myopia only | Active children, -5.00D and below | Young children, any prescription | Rapid progressors |
Lifestyle Factors That Support Myopia Control
Clinical interventions work best when combined with daily habits that are independently shown to reduce myopia onset and progression risk.
90+ minutes of outdoor time daily
Natural light stimulates dopamine release in the retina, which is thought to inhibit axial elongation. This is the most consistently supported environmental factor in myopia research.
20-20-20 rule for near work
Every 20 minutes of near work, take a 20-second break looking at something 20 feet away. This reduces sustained near-focal stress on the developing eye.
Limit sustained screen distance
Hold phones and tablets at least 30 to 40cm from the eyes. Avoid reading in dim light or lying on one side. Good posture during near work matters.
Avoid bright artificial light at night
Blue light from screens in the evening disrupts the circadian rhythm, which may affect dopamine signalling relevant to myopia. Reduce evening screen exposure and use warm-toned lighting.
Frequently Asked Questions
Related Topics
Book a Myopia Control Consultation in Chennai
Every dioptre of myopia prevented matters. Our COVD-certified specialists provide evidence-based myopia control with Ortho-K, low-dose atropine, and 6-monthly axial length monitoring. Book your child's consultation today.